Branford, CT (April 14, 2017): Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Gary Mathias, Chief Executive Officer, will present an overview of the company’s pipeline of lipid-based drugs for orphan gastrointestinal (GI) diseases. The presentation will take place at the Washington Marriott Wardman Park in Washington, D.C. at 3:30 pm ET on April 20th.
About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company pioneering the development of novel lipid-based drugs for orphan gastrointestinal (GI) diseases. Using proprietary HEALER™ chemistry platform, Thetis creates unique derivatives of bioactive lipids that have improved pharmaceutical properties and strong intellectual property protection. This technology unlocks the robust biology of lipids that are clinically or preclinically known to have efficacy in treating GI diseases. The company’s lead candidate TP-252 is being developed for the treatment of familial adenomatous polyposis (FAP), a rare genetic disease which has no approved drug therapies. TP-252 is a new molecular entity that delivers eicosapentaenoic acid free fatty acid (EPA-FFA), a bioactive lipid with demonstrated clinical efficacy in controlling colorectal polyp burden in FAP patients. Thetis is also developing TP-252 for the treatment of ulcerative colitis based on phase 2 clinical data showing that EPA-FFA prevents relapse in patients at higher risk of flares. By leveraging the established clinical efficacy and safety of EPA-FFA, Thetis anticipates moving its TP-252 programs rapidly into clinical development, facilitated by minimal non-clinical toxicology requirements and 505(b)(2) NDA submissions.